
Novel Drug a Potential ‘Game-Changer’ for Narcolepsy
An investigational oral selective orexin receptor 2 agonist (oveporexton, Takeda) demonstrated significantly improved measures of wakefulness, sleepiness, and cataplexy in a phase 2b study of adults with narcolepsy type 1 (NT1). NT1 is a chronic disorder …